



Nigeria

African Region



I. Epidemiological profile

Population (UN Population Division)	2017	%	Parasites and vectors
High transmission (>1 case per 1000 population)	145.8M	76	Major plasmodium species: P.falciparum: 100 (%) , P.vivax: 0 (%)
Low transmission (0-1 case per 1000 population)	45.1M	24	Major anopheles species: <i>An. gambiae</i> , <i>An. funestus</i> , <i>An. arabiensis</i> , <i>An. moucheti</i> , <i>An. melas</i> , <i>An. nili</i>
Malaria free (0 cases)	0	-	
Total	190.9M		
			Reported confirmed cases (health facility): 11 571 958 Estimated cases: 53.7M [36.3M, 75.9M]
			Confirmed cases at community level: 67 755
			Confirmed cases from private sector: 1 448 165
			Reported deaths: - Estimated deaths: 79.8K [62.5K, 97K]

II. Intervention policies and strategies

Intervention	Policies/Strategies	Yes/No	Year adopted	Medicine	Year adopted
ITN	ITNs/LLINs distributed free of charge	Yes	2001	Antimalaria treatment policy	
	ITNs/LLINs distributed to all age groups	Yes	2009		
IRS	IRS is recommended	Yes	2007	First-line treatment of unconfirmed malaria	AL; AS+AQ 2004
	DDT is used for IRS	No	-	First-line treatment of P. falciparum	AL; AS+AQ 2004
Larval control	Use of Larval Control	Yes	2010	For treatment failure of P. falciparum	QN 2004
				Treatment of severe malaria	AS; AM; QN 2004
IPT	IPT used to prevent malaria during pregnancy	Yes	2004	Treatment of P. vivax	-
Diagnosis	Patients of all ages should receive diagnostic test	Yes	2010	Dosage of primaquine for radical treatment of P. vivax	-
	Malaria diagnosis is free of charge in the public sector	No	-	Type of RDT used	-
Treatment	ACT is free for all ages in public sector	Yes	2009	Therapeutic efficacy tests (clinical and parasitological failure, %)	
	The sale of oral artemisinin-based monotherapies (oAMTs) is banned	-	-	Medicine	Year
	Single dose of primaquine (0.25 mg base/kg) is used as gametocidal medicine for P. falciparum	No	-	AL	2010-2011
	Primaquine is used for radical treatment of P. vivax	No	-	AL	2014-2014
	G6PD test is a requirement before treatment with primaquine	No	-	AS+AQ	2010-2011
	Directly observed treatment with primaquine is undertaken	No	-		
	System for monitoring of adverse reaction to antimalarials exists	Yes	-		
	ACD for case investigation (reactive)	No	-		
	ACD at community level of febrile cases (pro-active)	No	-		
	Mass screening is undertaken	No	-		
Surveillance	Uncomplicated P. falciparum cases routinely admitted	No	-	Resistance status by insecticide class (2010-2017) and use of class for malaria vector control (2017)	
	Uncomplicated P. vivax cases routinely admitted	No	-	Insecticide class	Years
	Case and foci investigation undertaken	No	-		(%) sites ¹
	Case reporting from private sector is mandatory	No	-		Vectors ²
					Used ³

¹Percent of sites for which resistance confirmed and total number of sites that reported data (n)

²Principal vectors that exhibited resistance

³Class used for malaria vector control in 2017